Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

AVN-211

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
AVN-211
Clinical data
Other namesCD-008-0173
Identifiers
  • 5,7-dimethyl-2-(methylsulfanyl)-3-(phenylsulfonyl)pyrazolo[1,5-a]pyrimidine
CAS Number
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC15H15N3O2S2
Molar mass333.42 g·mol−1
3D model (JSmol)
  • Cc1cc(n2c(n1)c(c(n2)SC)S(=O)(=O)c3ccccc3)C
  • InChI=1S/C15H15N3O2S2/c1-10-9-11(2)18-14(16-10)13(15(17-18)21-3)22(19,20)12-7-5-4-6-8-12/h4-9H,1-3H3
  • Key:KSAUCBGUWGWPDL-UHFFFAOYSA-N

AVN-211 (CD-008-0173) is adrug which acts as a highly selective5-HT6 receptorantagonist and is under development by Avineuro Pharmaceuticals for the treatment ofschizophrenia.[1][2][3] In early 2011, it successfully completedphase IIaclinical trials,[1][4] with benefits onpositive symptoms and someprocognitive effects observed,[5] and in mid 2013,phase IIb clinical trials for schizophrenia began.[6] Avineuro Pharmaceuticals also expressed intention to start clinical trials of AVN-211 forAlzheimer's disease in 2015.[6][7][needs update]

See also

[edit]

References

[edit]
  1. ^abEllenbroek BA, Cesura AM (13 October 2014)."Antipsychotics and the Dopamine-Serotonin Connection". In Celanire S, Poli S (eds.).Small Molecule Therapeutics for Schizophrenia. Springer. pp. 31, 37.ISBN 978-3-319-11502-3.
  2. ^Pharmacology of 5-HT6 receptors. Academic Press. 7 December 2010. pp. 164–.ISBN 978-0-12-384977-9.
  3. ^"Drug Development in Schizophrenia: Summary and Table".Pharmaceutical Medicine.28 (5):265–271. 2014.doi:10.1007/s40290-014-0070-6.ISSN 1178-2595.S2CID 8513976.
  4. ^"Avineuro Pharmaceuticals, Inc. Reports positive Phase 2a clinical proof of concept trial results on AVN-211, potent small molecule for treatment of schizophrenia". Avineuro Pharmaceuticals, Inc.
  5. ^Morozova MA, Lepilkina TA, Rupchev GE, Beniashvily AG, Burminskiy DS, Potanin SS, et al. (August 2014). "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study".CNS Spectrums.19 (4):316–323.doi:10.1017/S1092852913000394.PMID 23768250.S2CID 25486838.
  6. ^ab"Avineuro Pharmaceuticals, Inc. Announces beginning of Phase 2b clinical studies of AVN-211, potent small molecule for treatment of schizophrenia". Avineuro Pharmaceuticals, Inc.
  7. ^Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA (March 2016). "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease".Molecular Pharmaceutics.13 (3):945–963.doi:10.1021/acs.molpharmaceut.5b00830.PMID 26886442.

External links

[edit]
Typical
Disputed
Atypical
Others
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=AVN-211&oldid=1269663414"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp